MoonLake Immunotherapeutics(MLTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MLTX MoonLake Immunotherapeutics

盘后交易 10-19 16:20:25 EDT

9.75

+0.20

+2.09%

盘后9.75

+0.000.00%

16:10 EDT

最高9.86	最低9.50	成交量90.64万
今开9.57	昨收9.55	日振幅3.80%
总市值8.30亿	流通市值5.41亿	总股本8,511万
成交额879.48万	换手率1.63%	流通股本5,547万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":9.75,"timestamp":1792440000000,"preClose":9.55,"halted":0,"volume":906379,"hourTrading":{"tag":"盘后","latestPrice":9.75,"preClose":9.75,"latestTime":"16:10 EDT","volume":9602,"amount":93619.5,"timestamp":1792440604777,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.020942408376963276,"floatShares":55468400,"shares":85106685,"eps":-3.813939,"marketStatus":"盘后交易","change":0.2,"latestTime":"10-19 16:20:25 EDT","open":9.57,"high":9.8625,"low":9.5,"amount":8794773,"amplitude":0.037958,"askPrice":10,"askSize":1,"bidPrice":9.47,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.813939,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792454400000},"marketStatusCode":4,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":9.55,"preHourTrading":{"tag":"盘前","latestPrice":9.6703,"preClose":9.55,"latestTime":"09:16 EDT","volume":859,"amount":8173.719151,"timestamp":1792415812068,"change":0.1203,"changeRate":0.012597,"amplitude":0.036649},"postHourTrading":{"tag":"盘后","latestPrice":9.75,"preClose":9.75,"latestTime":"16:10 EDT","volume":9602,"amount":93619.5,"timestamp":1792440604777,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.577553,"impliedVol":0.8254,"impliedVolPercentile":0.3466},"requestUrl":"/m/hq/s/MLTX","defaultTab":"news","newsList":[{"id":"1154738602","title":"MoonLake Immunotherapeutics 公布 III 期 Izar-1 试验结果：60 mg Sonelokimab 在 16 周达成所有临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1154738602","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154738602?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:05","pubTimestamp":1786359924,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics 今日宣布，其 III 期 Izar-1 临床试验在 16 周时，针对 60 mg 剂量的 Sonelokimab 药物，成功实现了所有预设的临床终点。这一里程碑式的突破，为该公司在免疫治疗领域的研发注入强劲动力。试验结果不仅验证了药物疗效，更彰显了其潜在的治疗价值，令市场为之振奋。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136601110","title":"MoonLake公布Sonelokimab治疗银屑病关节炎III期Izar-1试验积极顶线结果：所有临床终点均显著改善，并发布2026年第二季度财报","url":"https://stock-news.laohu8.com/highlight/detail?id=1136601110","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136601110?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:01","pubTimestamp":1786359675,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics今日宣布，其关键候选药物Sonelokimab在针对银屑病关节炎的III期Izar-1临床试验中取得了积极的顶线结果。这一里程碑式的进展，不仅为饱受该疾病困扰的患者带来了新的希望，也进一步验证了Sonelokimab的潜在治疗价值。与此同时，公司还同步披露了截至2026年6月30日的第二季度财务报告。公司管理层表示，将基于这些振奋人心的结果，积极与监管机构沟通，以加速Sonelokimab的后续开发与上市申请进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127733506","title":"MoonLake Immunotherapeutics宣布公开募股后，盘后股价下跌约4%至21.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127733506","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127733506?lang=zh_cn&edition=full","pubTime":"2026-06-23 04:05","pubTimestamp":1782158718,"startTime":"0","endTime":"0","summary":"在宣布公开市场股票发行计划后，生物技术公司MoonLake Immunotherapeutics的股价在盘后交易时段应声下挫。其股价下跌了大约百分之四，最终报收于每股21.28美元。这一市场反应凸显了投资者对于股权稀释可能性的即时关切，也反映了在融资消息公布后，市场情绪通常会出现的短期波动。尽管股价有所回调，但此次募资行动本身旨在为公司未来的研发与运营注入新的资本活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172533496","title":"MoonLake Immunotherapeutics 宣布拟进行1.5亿美元A类普通股及预融资权证公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1172533496","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172533496?lang=zh_cn&edition=full","pubTime":"2026-06-23 04:02","pubTimestamp":1782158566,"startTime":"0","endTime":"0","summary":"生物技术公司MoonLake Immunotherapeutics披露了一项新的融资计划。该公司宣布，拟进行一项总额高达1.5亿美元的混合证券公开发行。\n此次发行将包含其A类普通股以及与之挂钩的预融资权证。公司表示，计划将此次发行所募集的净资金主要用于推进其核心临床管线的发展，包括为相关研发活动提供资金，并补充营运资本及用于其他一般公司用途。\n本次发行的具体条款，包括证券数量、发行价格等，将根据市场情况及其他因素最终确定。承销商将被授予一项期权，可在发行定价后30天内额外购买最多15%的拟发行证券。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110343641","title":"MoonLake公布Sonelokimab治疗化脓性汗腺炎三期Vela项目第52周结果，并确认2026年6月22日投资者日","url":"https://stock-news.laohu8.com/highlight/detail?id=1110343641","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110343641?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:01","pubTimestamp":1782075675,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics宣布了其候选药物Sonelokimab在治疗化脓性汗腺炎的三期Vela项目中第52周的试验结果。同时，公司确认将于2026年6月22日举行投资者日活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121299302","title":"MoonLake Immunotherapeutics宣布美国FDA接受MIRA与VELA-TEEN试验数据用于Sonelkimab的BLA提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1121299302","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121299302?lang=zh_cn&edition=full","pubTime":"2026-05-10 21:12","pubTimestamp":1778418750,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics宣布，其与美国食品药品监督管理局（FDA）就Sonelkimab生物制品许可申请（BLA）提交前的最终会议取得了积极成果。FDA已正式接受来自MIRA试验和VELA-TEEN试验的数据，这些数据将支持该药物用于治疗化脓性汗腺炎（HS）的BLA提交。\n公司计划于2026年9月底前完成Sonelkimab针对HS的BLA提交。此次进展标志着该候选药物在监管审批道路上迈出了关键一步。\n此外，MoonLake Immunotherapeutics同期公布了其2026年第一季度的财务业绩。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115143826","title":"MoonLake Immunotherapeutics公布与美国FDA最终BLA前会议的积极结果及2026年第一季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1115143826","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115143826?lang=zh_cn&edition=full","pubTime":"2026-05-10 21:02","pubTimestamp":1778418139,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics宣布，其与美国食品药品监督管理局（FDA）就关键候选产品进行的最终生物制品许可申请（BLA）前会议取得了积极成果。公司管理层与监管机构就提交BLA所需的数据包和路径达成了一致，这标志着其药物开发进程中的一个重要监管里程碑。\n与此同时，公司公布了2026年第一季度的财务业绩。财报显示，本季度研发投入显著，主要用于推进其核心管线项目。尽管研发费用增加导致净亏损有所扩大，但公司现金及现金等价物状况依然稳健，足以支持其未来数年的运营和关键临床开发计划。管理层对取得的进展表示满意，并期待按计划向FDA正式提交BLA申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162608526","title":"MoonLake Immunotherapeutics：FDA接受Mira及Vela-Teen试验数据，用于Sonelkimab生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1162608526","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162608526?lang=zh_cn&edition=full","pubTime":"2026-05-10 21:01","pubTimestamp":1778418072,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics宣布，美国食品药品监督管理局已接受其Mira试验及Vela-Teen试验的数据，这些数据将用于支持其候选药物Sonelkimab的生物制品许可申请提交。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168707494","title":"异动解读 | Moonlake Immunotherapeutics去年大亏3.19亿,股价盘中大跌5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=1168707494","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168707494?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:00","pubTimestamp":1741035628,"startTime":"0","endTime":"0","summary":"生物科技公司Moonlake Immunotherapeutics(MLTX.US)今日盘中大跌5%。\n\n引发该公司股价暴跌的原因很可能是其2024财年表现远逊预期。财报显示,Moonlake去年净利润同比惨淡,亏损高达1.19亿美元,同比减少230.46%。公司目前仍处于无收入阶段,每股亏损1.89美元。\n\n此外,该公司资产负债表状况堪忧,总负债24.54百万美元,资产负债率高达0.20,流动性也相当紧张,流动比率仅为0.22。尽管分析师给予该公司目标价均价在80.92美元,但显然已与当前表现存在差距。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Moonlake Immunotherapeutics去年大亏3.19亿,股价盘中大跌5%。","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516665994","title":"Moonlake Immunotherapeutics盘中异动 股价大跌5.06%报39.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516665994?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:58","pubTimestamp":1741035513,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时58分，Moonlake Immunotherapeutics股票出现波动，股价快速跳水5.06%。截至发稿，该股报39.65美元/股，成交量17.8904万股，换手率0.28%，振幅6.72%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体跌幅为0.17%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304045833989a64da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304045833989a64da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516592686","title":"Moonlake Immunotherapeutics2024财年实现净利润-1.19亿美元，同比减少230.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516592686","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516592686?lang=zh_cn&edition=full","pubTime":"2025-03-03 18:00","pubTimestamp":1740996029,"startTime":"0","endTime":"0","summary":"3月3日，Moonlake Immunotherapeutics公布财报，公告显示公司2024财年净利润为-1.19亿美元，同比减少230.46%；其中营业收入为0.00美元，每股基本收益为-1.89美元。从资产负债表来看，Moonlake Immunotherapeutics总负债24.54百万美元，其中短期债务1.37百万美元，资产负债比为0.20，流动比率为0.22。机构评级：截至2025年3月3日，当前有13家机构对Moonlake Immunotherapeutics目标价做出预测，其中目标均价为80.92美元，其中最低目标价为65.00美元，最高目标价为108.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303180036abe5da37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303180036abe5da37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514861722","title":"Moonlake Immunotherapeutics盘中异动 股价大涨5.01%报42.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514861722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514861722?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:42","pubTimestamp":1740598954,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时42分，Moonlake Immunotherapeutics股票出现波动，股价急速上涨5.01%。截至发稿，该股报42.77美元/股，成交量40.5569万股，换手率0.64%，振幅6.69%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体跌幅为0.46%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227034234a2553be3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227034234a2553be3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159720103","title":"MoonLake 2024年第四季度每股亏损$(0.72) 超出预期$(0.60)，预计截至2026年底现金、现金等价物和短期可出售债务证券余额为4.48亿美金","url":"https://stock-news.laohu8.com/highlight/detail?id=1159720103","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159720103?lang=zh_cn&edition=full","pubTime":"2025-02-26 20:42","pubTimestamp":1740573763,"startTime":"0","endTime":"0","summary":"MoonLake报告季度每股亏损$，比分析师的共识预期$多出20%。这比去年同期每股亏损$增加了620%。以上内容来自Benzinga Earnings专栏，原文如下：MoonLake  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 20 percent. This is a 620 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MoonLake 2024年第四季度每股亏损$(0.72) 超出预期$(0.60)，预计截至2026年底现金、现金等价物和短期可出售债务证券余额为4.48亿美金","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509235033","title":"Moonlake Immunotherapeutics盘中异动 早盘股价大涨5.04%报46.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509235033","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509235033?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:18","pubTimestamp":1738772289,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日00时18分，Moonlake Immunotherapeutics股票出现异动，股价快速上涨5.04%。截至发稿，该股报46.34美元/股，成交量9.2296万股，换手率0.15%，振幅4.58%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体涨幅为1.36%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206001809a23a9438&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206001809a23a9438&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MLTX","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508229881","title":"Moonlake Immunotherapeutics盘中异动 股价大跌5.00%报43.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508229881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508229881?lang=zh_cn&edition=full","pubTime":"2025-02-04 03:36","pubTimestamp":1738611404,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日03时36分，Moonlake Immunotherapeutics股票出现波动，股价大幅下挫5.00%。截至发稿，该股报43.69美元/股，成交量12.7106万股，换手率0.20%，振幅6.04%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体跌幅为0.11%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020403364496172687&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020403364496172687&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505277159","title":"Moonlake Immunotherapeutics盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505277159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505277159?lang=zh_cn&edition=full","pubTime":"2025-01-21 23:25","pubTimestamp":1737473139,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日23时25分，Moonlake Immunotherapeutics股票出现波动，股价快速拉升5.00%。截至发稿，该股报46.00美元/股，成交量9.8481万股，换手率0.16%，振幅4.22%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体涨幅为1.29%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121232540986e3dc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121232540986e3dc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504516192","title":"Moonlake Immunotherapeutics盘中异动 早盘股价大涨8.13%报44.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504516192","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504516192?lang=zh_cn&edition=full","pubTime":"2025-01-17 22:31","pubTimestamp":1737124279,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日22时31分，Moonlake Immunotherapeutics股票出现异动，股价急速拉升8.13%。截至发稿，该股报44.84美元/股，成交量3.1407万股，换手率0.05%，振幅0.16%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体涨幅为0.73%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117223119a225bba8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117223119a225bba8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504928311","title":"Moonlake Immunotherapeutics盘中异动 临近收盘大幅跳水5.33%报41.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504928311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504928311?lang=zh_cn&edition=full","pubTime":"2025-01-17 04:56","pubTimestamp":1737061002,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日04时56分，Moonlake Immunotherapeutics股票出现波动，股价大幅跳水5.33%。截至发稿，该股报41.63美元/股，成交量41.23万股，换手率0.65%，振幅7.16%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体跌幅为0.90%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117045642abada082&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117045642abada082&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503642619","title":"Moonlake Immunotherapeutics盘中异动 急速拉升5.51%报49.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503642619","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503642619?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951542,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Moonlake Immunotherapeutics股票出现波动，股价大幅上涨5.51%。截至发稿，该股报49.06美元/股，成交量4818股，换手率0.01%，振幅2.30%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体涨幅为0.77%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223222a222fe19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223222a222fe19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503586677","title":"Moonlake Immunotherapeutics盘中异动 早盘大幅下挫5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503586677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503586677?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:52","pubTimestamp":1736779928,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时52分，Moonlake Immunotherapeutics股票出现异动，股价急速下跌5.65%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体跌幅为1.42%。其相关个股中，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为4869.64%、3040.40%、406.02%，振幅较大的相关个股有Kairos Pharma, Ltd.、Salarius Pharmaceuticals, Inc.、Phio Pharmaceuticals Corp.，振幅分别为118.35%、104.79%、92.90%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家临床阶段的生物技术公司，致力于利用纳米体技术开发免疫疾病的新一代的药物，包括炎症性皮肤和关节疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113225208a22044ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113225208a22044ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KAPA","KAIR","MLTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":-0.1174},{"period":"1month","weight":-0.2335},{"period":"3month","weight":-0.5147},{"period":"6month","weight":-0.4793},{"period":"1year","weight":0.0181},{"period":"ytd","weight":-0.2754}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MoonLake Immunotherapeutics是一家于2020年8月13日注册的开曼群岛公司，该公司是一家临床阶段的生物技术公司，致力于推进变革性疗法，以解决炎症性皮肤和关节疾病方面的重大未满足需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.01118},{"month":2,"riseRate":0.5,"avgChangeRate":0.083781},{"month":3,"riseRate":0.666667,"avgChangeRate":0.033144},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.114037},{"month":5,"riseRate":0.5,"avgChangeRate":0.100872},{"month":6,"riseRate":0.833333,"avgChangeRate":0.149159},{"month":7,"riseRate":0.5,"avgChangeRate":0.052272},{"month":8,"riseRate":0.5,"avgChangeRate":0.044509},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.176073},{"month":10,"riseRate":0.5,"avgChangeRate":0.02023},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.079459}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MoonLake Immunotherapeutics(MLTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MoonLake Immunotherapeutics(MLTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}